Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-02-11 4:47 pm Purchase |
2021-12-31 | 13G | Gemini Therapeutics, Inc. GMTX |
SUVRETTA CAPITAL MANAGEMENT LLC | 237,227 5.500% |
13,942 (+6.24%) |
Filing History |
| 2022-02-11 4:45 pm Purchase |
2021-12-31 | 13G | Sio Gene Therapies Inc. SIOX |
SUVRETTA CAPITAL MANAGEMENT LLC | 5,914,000 8.100% |
425,000 (+7.74%) |
Filing History |
| 2022-02-11 4:38 pm Purchase |
2021-12-31 | 13G | Cano Health, Inc. CANO |
SUVRETTA CAPITAL MANAGEMENT LLC | 105,476 5.800% |
18,387 (+21.11%) |
Filing History |
| 2022-02-11 4:37 pm Purchase |
2021-12-31 | 13G | Mereo BioPharma Group plc MREO |
SUVRETTA CAPITAL MANAGEMENT LLC | 45,710,335 8.400% |
13,882,835 (+43.62%) |
Filing History |
| 2022-02-11 4:24 pm Purchase |
2021-12-31 | 13G | EyePoint Pharmaceuticals, Inc. EYPT |
SUVRETTA CAPITAL MANAGEMENT LLC | 3,482,109 9.990% |
1,886,945 (+118.29%) |
Filing History |
| 2022-02-11 4:19 pm Purchase |
2021-12-31 | 13G | Fulcrum Therapeutics, Inc. FULC |
SUVRETTA CAPITAL MANAGEMENT LLC | 2,375,571 5.900% |
578,653 (+32.20%) |
Filing History |
| 2021-12-16 4:32 pm Purchase |
2021-12-06 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
SUVRETTA CAPITAL MANAGEMENT LLC | 102,840 5.200% |
102,840 (New Position) |
Filing History |
| 2021-12-10 4:31 pm Purchase |
2021-11-30 | 13G | Sutro Biopharma, Inc. STRO |
SUVRETTA CAPITAL MANAGEMENT LLC | 2,408,395 5.200% |
2,408,395 (New Position) |
Filing History |
| 2021-12-09 4:31 pm Purchase |
2021-11-29 | 13G | Kura Oncology, Inc. KURA |
SUVRETTA CAPITAL MANAGEMENT LLC | 3,503,419 5.300% |
3,503,419 (New Position) |
Filing History |
| 2021-11-29 4:39 pm Purchase |
2021-11-18 | 13G | Bolt Biotherapeutics, Inc. BOLT |
SUVRETTA CAPITAL MANAGEMENT LLC | 2,230,250 6.000% |
2,230,250 (New Position) |
Filing History |
| 2021-10-15 4:49 pm Purchase |
2021-10-05 | 13G | Gemini Therapeutics, Inc. GMTX |
SUVRETTA CAPITAL MANAGEMENT LLC | 223,284 5.200% |
223,284 (New Position) |
Filing History |
| 2021-09-17 4:54 pm Purchase |
2021-09-07 | 13G | KalVista Pharmaceuticals, Inc. KALV |
SUVRETTA CAPITAL MANAGEMENT LLC | 1,296,452 5.300% |
1,296,452 (New Position) |
Filing History |
| 2021-08-20 4:36 pm Purchase |
2021-08-10 | 13G | Marinus Pharmaceuticals, Inc. MRNS |
SUVRETTA CAPITAL MANAGEMENT LLC | 2,052,358 5.600% |
2,052,358 (New Position) |
Filing History |
| 2021-08-10 5:05 pm Purchase |
2021-08-04 | 13G | Fulcrum Therapeutics, Inc. FULC |
SUVRETTA CAPITAL MANAGEMENT LLC | 1,796,918 5.500% |
1,796,918 (New Position) |
Filing History |
| 2021-07-30 4:42 pm Purchase |
2021-07-20 | 13G | Cano Health, Inc. CANO |
SUVRETTA CAPITAL MANAGEMENT LLC | 87,089 5.100% |
87,089 (New Position) |
Filing History |
| 2021-07-26 5:21 pm Purchase |
2021-07-14 | 13G | EyePoint Pharmaceuticals, Inc. EYPT |
SUVRETTA CAPITAL MANAGEMENT LLC | 1,595,164 5.600% |
1,595,164 (New Position) |
Filing History |
| 2021-05-07 4:46 pm Purchase |
2021-04-28 | 13G | Benitec Biopharma Inc. BNTC |
SUVRETTA CAPITAL MANAGEMENT LLC | 45,235 9.800% |
45,235 (New Position) |
Filing History |
| 2021-04-23 4:30 pm Purchase |
2021-04-14 | 13G | Fintech Acquisition Corp. V FTCV |
SUVRETTA CAPITAL MANAGEMENT LLC | 1,901,890 7.400% |
1,901,890 (New Position) |
Filing History |
| 2021-04-22 4:02 pm Purchase |
2021-04-12 | 13G | Otonomy, Inc. OTIC |
SUVRETTA CAPITAL MANAGEMENT LLC | 6,018,878 9.990% |
6,018,878 (New Position) |
Filing History |
| 2021-04-02 10:59 am Purchase |
2021-03-23 | 13G | Therapeutics Acquisition Corp. RACA |
SUVRETTA CAPITAL MANAGEMENT LLC | 1,095,400 7.800% |
1,095,400 (New Position) |
Filing History |